You are about to be redirected to a site intended for people with primary HLH or their caregivers.
You are being redirected to a third party website.
Sobi takes no responsibility for the content of this website.
For patients with refractory, recurrent, or progressive disease or intolerance to conventional HLH therapy.
(95% CI: 0.42, 0.81; P = 0.013)
Gamifant was shown to neutralize IFNγ as measured by a rapid and sustained reduction in the plasma concentrations of CXCL9, a chemokine induced almost exclusively by IFNγ.See how Gamifant works
Primary hemophagocytic lymphohistiocytosis (HLH) is a rare hyperinflammatory condition that mostly affects children, but can also occur in adults and teenagers.3-6
Gamifant reduces the inflammatory symptoms of primary HLH by neutralizing IFNγ.1
Gamifant is given as an intravenous infusion twice a week until hematopoietic stem cell transplantation (HSCT) is performed.1
Download the Start Form now or contact Gamifant Patient Services at 833.597.6530.